Drug Channels delivers timely analysis and provocative opinions on pharmaceutical economics and the drug distribution system. It is written by Adam J. Fein, Ph.D., one of the country's foremost experts on pharmaceutical economics and channel strategy. Drug Channels reaches an engaged, loyal and growing audience of more than 24,000 subscribers. Learn more...

Monday, March 25, 2019

CBI’s 21st Annual Medicaid and Government Pricing Congress

CBI’s 21st Annual Medicaid and Government Pricing Congress
May 20-22, 2019 | Orlando, FL
www.cbinet.com/medicaid

Exclusive Offer – Register by April 5th
and save $500* with promo code MDCDC5.

As our healthcare system proves to be more turbulent than ever, with a slew of regulatory and political announcements, hearings, the never-ending drug pricing debate, and most recently, FDA Commissioner Scott Gottlieb announcing his resignation and talks of doing away with rebates and/or PBMs, the time has never been more opportune to convene with industry colleagues at the 21st Annual Medicaid and GP Congress this Spring in Orlando.

The 2019 agenda boasts 55+ speakers, 30+ customizable sessions and 7 hours of dedicated networking time. Bio/pharma, regulatory and government experts representing Johnson & Johnson, OIG, Sunovion, Pfizer, Ingenus, Chiesi, AstraZeneca, Amneal, Hikma, CMS, Bristol-Myers Squibb, Apotex, Fresenius Medical Care, UCB, Alvogen, PhRMA, Jazz Pharmaceuticals, Insmed, Arbor Pharmaceuticals, Eisai, Goldwater Institute, Amicus Therapeutics and many others are set to drive the dialogue.

Stay on the pulse with timely, up-to-the-minute insights on the political and regulatory landscape, industry hot topics and best practices:
  • Political and Legislative Trends
  • 340B Guidance
  • State and Federal Transparency Regulations
  • Civil Monetary Penalties
  • Value-Based Frameworks
  • State Invoicing and Disputes
  • Contracting with PBMs
  • Changes to Medicare
  • Bona Fide Service Fees
  • GTN and Accruals
  • And many other critical topics. Download the complete agenda.
Drug Channels Readers – Register today with promo code MDCDC5 and save $500.*

*Discount offer valid through 4/5/2019; applies to standard rates only and may not be combined with other offers, categories, promotions or applied to an existing registration. Offer not valid on workshop-only or non-profit registrations.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Wednesday, March 20, 2019

A World Without Rebates: Predictions for How the Channel Will Evolve and Why Drug Prices Will Go Down

Two years ago on Drug Channels, I wrote about a shift from rebates to discounts as a black swan event—a massively important yet unexpected break from current practice.

Given recent developments, I believe that we are moving ever closer to a world without rebates. Yet there are many unanswered questions were such a radical shift to occur.

As I see it, a world without rebates would force manufacturers to use net price as a competitive weapon. If PBMs and payers behave logically, then drug prices would drop as manufacturers are forced to compete more aggressively for prescriptions.

These conclusions are based on the predictions about market changes that I describe below. Other key implications include:
  • Winner-take-all auctions and narrow formularies for categories with therapeutically comparable products
  • Broader formularies to encourage indication-based price competition for other therapeutic categories
  • Faster patient access to new drugs with superior efficacy for certain subgroups of patients
  • Fewer pharmacy benefit benefit tiers and a greater ability for physicians and patients to make cost/value tradeoffs
  • The popping of the gross-to-net bubble and declines in brand-name list prices
  • Slower growth in drug prices
This is a longer-than-average post, but I still only scratch the surface in speculating how our world could change. If the black swan continues to spread its wings, I’ll expand in future posts on implications for drug makers, pharmacy benefit managers (PBMs), wholesalers, pharmacies, health plans, and patients. As always, I encourage you to leave your comments and ideas below.


SAVE THE DATE: Drug Channels Institute will hold a special live, interactive webinar titled Competing in a World Without Rebates on April 12, 2019, at 12 PM ET. Details and registration information will be announced in the first week of April.

Monday, March 18, 2019

CBI’s Real-Time Benefit Check & ePrior Authorization Summit

CBI’s Real-Time Benefit Check & ePrior Authorization Summit
May 14-15, 2019 | Philadelphia, PA
www.cbinet.com/eprior

CBI’s Real-Time Benefit Check & ePrior Authorization Summit is your chance to stay on the pulse of groundbreaking advancements and innovations in real-time benefit verification and prior authorizations in this evolving and complex healthcare environment. Convene with industry stakeholders from bio/pharma, PBMs, payers, health systems, prescribers and system solution providers to discuss the latest in standards, adoption and best practices to enable streamlined healthcare team workflow and quicker access to therapy to improve patient outcomes.

Visit www.cbinet.com/eprior for further details and to register. Drug Channels readers will save $300 off the standard rate when they use promo code ANS268 and register prior to April 5th. *

Download the agenda here and see in-depth coverage on critical issues, such as:
  • Real-Time Prescription Benefit and ePrior Authorization
  • New Regulations from CMS on Medicare Part D and RTBT
  • Implementing Medical Specialty Drug ePA
  • eBV and ePA Frameworks for the Future of the Medical Benefit
  • Reducing Friction in the Prescribing Process
  • Fixing ePrior from a Prescriber Perspective
  • Collaborating to Improve Patient Outcomes
  • Low Utilization of RTBC and ePA Among Stakeholders
  • Turnaround Time for Accelerated Patient Access to Therapy
  • Real-Time Benefit Data at the Point of Prescription
  • HL7 Da Vinci Project for Value-Based Care Interactions between Payers and Providers
Featured Sessions:
  • Trailblazer Talk- Hear Updates on Industry Scorecard
    • Melissa Paige, Oncology/Infusion Patient Access Principal Coordinator, University of Virginia
    • Eric Weidmann, M.D., Chief Medical Officer, eMDs
    • Evan Grossman, Vice President, Integration Services, athenahealth
  • Working Group for Specialty Pharmacy Advancements and Standard Updates in Real-Time Prescription Benefit and ePrior Authorization
    • John Klimek, R.Ph., Senior Vice President, Standards and Industry Information Technology, NCPDP
Visit www.cbinet.com/eprior for further details and to register. Drug Channels readers will save $300 off the standard rate when they use code ANS268 and register prior to April 5th. *

CBI will see you there!

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates, clinic/hospital rates, non-profit rates other offers. Other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Tuesday, March 12, 2019

Employers Are Absorbing Even More Manufacturer Rebates from Their PBMs

The likelihood of a radical restructuring of the U.S. drug channel has never been greater. A serious effort exists to remove or decrease the role of rebates.

Today, we shed light on one crucial aspect of the current rebate system: how employer-sponsored health plans access the billions of dollars in manufacturer rebates that are negotiated by their pharmacy benefit managers (PBMs). For this analysis, we rely on the Pharmacy Benefit Management Institute’s (PBMI) excellent new reports.

As you will see, employers are receiving an increasing share of the rebate money collected by pharmacy benefit managers. However, employers’ rebate agreements with PBMs vary widely. Important differences also exist in rebate arrangements for traditional vs. specialty drugs.

Despite these data, we still don’t know how much of these rebates offset out-of-pocket costs for the patients whose prescriptions generated the rebate funds. As I warned last August: The focus of rebate reform will turn from PBMs to the plan sponsors that are absorbing rebate dollars.

Monday, March 11, 2019

3rd Annual Manufacturers’ 340B Summit

3rd Annual Manufacturers’ 340B Summit
May 16-17, 2019 | Philadelphia, PA
www.worldcongress.com/manufacturers340B

Join pharmaceutical manufacturers, legal experts, thought leaders, and leading regulatory strategists at World Congress’ 3rd Annual Manufacturers’ 340B Summit, May 16-17, in Philadelphia. This event is your first opportunity of 2019 to ensure you have the internal strategies in place to effectively execute 340B processes.

Register with promo code DC200 and save an additional $200 on current early bird rates.

How will you benefit from attending?
  • Review the scope of the 340B Program and possible changes to the program
  • Utilize data to identify duplicate discounts and other inconsistencies
  • Explore challenges of contract pharmacies and solutions that work for all stakeholders
  • Evaluate the implications of penny pricing, limited, distribution networks, ceiling price calculation, and civil monetary penalties
  • Survey best practices for working with the states and covered entities
Shouldn’t you be there?

Register with promo code DC200 and save an additional $200 on current early bird rates.
Can’t leave the office? Live stream this event from the convenience of your office.

This event, co-located with the 4th Annual Covered Entities’ 340B Summit, provides comprehensive coverage of the 340B program.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Friday, March 08, 2019

Delivering an Enhanced Patient and Prescriber Experience for Personalized Therapies

Today’s guest post comes from Rob Brown, VP/GM of Pharmacy Solutions at McKesson Life Sciences.

Rob provides insights on designing patient-centric channel strategies. He also reviews the role of centralized hub services with an integrated specialty pharmacy.

Click here to download McKesson’s case study. It describes how an emerging biotech company streamlined access for patients with an acute complex condition.

Read on for Rob’s insights.

Tuesday, March 05, 2019

NEW: The 2019 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

I am pleased to announce our new 2019 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers, available for purchase and immediate download.
We’re offering special discounted pricing if you order before March 22, 2019!

The 2019 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers is the only resource of its kind available anywhere. With 180 proprietary charts, exhibits, and data tables, the report provides the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing, reimbursement, and dispensing system.

The 2019 edition has been significantly restructured since last year’s edition. Many sections and chapters have been expanded or reorganized to better cover the latest industry developments. Throughout the report, we have added new industry data sources, deepened our coverage of many topics, added more trending information.

Below, you can read more info and some behind-the-scenes tidbits. See page viii of the free report overview for a summary of the many significant changes and updates in this 2019 edition. Happy reading!

P.S. If you would like to pay by corporate purchase order or check, please email Tamra Feldman. If you preordered the report, you should have already received an email with download instructions. Please contact us if you did not receive the email.

Monday, March 04, 2019

Join Me for Asembia’s Specialty Pharmacy Summit 2019

Asembia’s Specialty Pharmacy Summit 2019
April 29 to May 2, 2019 | Las Vegas
www.asembiasummit.com

Please join me at Asembia's Specialty Pharmacy Summit 2019 which will take place from April 29 to May 2, 2019 in Las Vegas.

This is a must-attend event for anyone connected to specialty pharmacy. You'll meet an impressive diversity of people from pharmacies, manufacturers, health plans, wholesalers, hospital systems, pharmacy benefit managers, patient advocacy groups, and more. Click here to view the agenda.

This year, I will again lead the Featured Session, titled Specialty Pharmacy Industry Outlook: What's Next? I'll be joined by Doug Long from IQVIA and Lisa Gill from J.P. Morgan Securities. And of course, I'm looking forward to another epic selfie!

Here's my review of last year's Summit: Reflections from #Asembia18: The State of Specialty Pharmacy 2018.

Read on for more details about this great specialty pharmacy event and register now. See you in Vegas!

A MESSAGE FROM ASEMBIA

As the nation’s largest annual healthcare conference for specialty pharmacy, Asembia’s 2019 Specialty Pharmacy Summit will welcome 6,500+ attendees from over 1,200 pharmacy providers, health systems, pharma/biotech manufacturers, payers, drug wholesalers and many other specialty pharmacy stakeholders.

Don’t miss this unique opportunity to gain in-depth understanding of specialty pharmacy from industry experts who share current information and insightful commentary on the many facets of the $150+ billion specialty pharmacy channel.

The value-packed 2019 agenda includes interactive business seminars, continuing education sessions, business workshops, extraordinary networking events and engaging exhibits.

Register and learn more at www.asembiasummit.com.

Watch the 2018 Video Highlights.


Asembia's 2018 Specialty Pharmacy Summit - Event Highlights from Asembia on Vimeo.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Thursday, February 28, 2019

Drug Channels News Roundup, February 2019: Diplomat’s Troubles, Sanofi’s Gross-to-Net Bubble, and the Legality of Accumulators

Winter—or at least February—is almost over! Celebrate the imminent return of spring with our selection of noteworthy news from around the drug channel. In this issue:
  • My $0.02 on Diplomat’s failures and the new realities of specialty pharmacy
  • Sanofi’s 2018 gross-to-net bubble
  • Legal issues for copay accumulators
Plus, The Onion reports a health insurance miracle!

P.S. My @DrugChannels Twitter account now has more than 7,000 followers. Join the fun for my daily commentary on the industry’s news.

Tuesday, February 26, 2019

The Top 15 U.S. Pharmacies of 2018: M&A Reshapes the Market

Next week, Drug Channels Institute will release our 2019 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. It’s the tenth edition of our popular and comprehensive examination of the entire drug pricing, reimbursement, and dispensing system.

The exhibit below—one of 180 in our new report—provides a first look at the 15 largest pharmacies, ranked by total U.S. prescription dispensing revenues for calendar year 2018.

As you will see, vertical and horizontal mergers and acquisitions are reshaping the pharmacy and PBM industries—and enabling the big to get even bigger. I highlight some of the major transactions that affected our ranking.

For a sneak peek at the complete report, click here to download a free pre-publication draft overview (including the table of contents and a list of exhibits).

Monday, February 25, 2019

CBI’s 5th Annual Formulary, Copay and Access Summit

CBI’s 5th Annual Formulary, Copay and Access Summit
April 9-11, 2019 | San Francisco, CA
www.cbinet.com/formulary

Accumulator programs, state-level copay legislation, formulary exclusions, high-deductible plans, changes in benefit design, NDC blocks, step therapy programs - the challenges continue to arise. This April, the industry comes together to tackle these topics and more at the Formulary, Copay and Access Summit in San Francisco.

Visit www.cbinet.com/formulary for further details and to register. Drug Channels readers will save $300 off the standard rate when they use promo code KRA435 and register prior to March 22nd.*

Download the agenda here and see in-depth coverage on critical issues, such as:
  • Explore perspectives on accumulator adjustment programs and identify trends for the future
  • Demystify proposed legislations and policies for lower drug prices
  • Overcome challenges of high-deductible plans, copay caps and the evolving healthcare landscape
  • Gain insight on strategies for fast tracking prior authorization and copay assistance for specialty prescriptions
  • Gain insight on key stakeholder challenges to discover new methods for manufacturers to collaborate with payers, pharmacists and physicians to improve patient outcomes
  • Develop best practices to communicate with field reps when there are issues with co-pay cards
  • Break down rebates and reimbursements and the impact on pricing strategies
Visit www.cbinet.com/formulary for further details and to register. Drug Channels readers will save $300 off the standard rate when they use promo code KRA435 and register prior to March 22nd.*

Wait a minute – we almost forgot the most exciting part! On April 9th, benefit from a pre-conference workshop on Copay Accumulator Programs, where experts in the field will discuss navigating the complexities and impact of the emerging cost-shifting benefit design. You can tack this workshop on to your Formulary Summit registration, or just attend the workshop itself. Learn more here.

CBI will see you there!

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates, clinic/hospital rates, non-profit rates other offers. Other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Wednesday, February 20, 2019

How Health Plans Profit—and Patients Lose—From Highly-Rebated Brand-Name Drugs

My Wall Street Journal op-ed (Don’t Blame Drug Prices on ‘Big Pharma’) has received a lot of attention.

Especially notable was a letter to the editor from American Health Insurance Plans (AHIP). It claims that “the savings that insurance providers negotiate are returned directly to consumers through lower premiums and out-of-pocket costs."

Don’t believe this misleading half-truth. It distorts the primary argument of my WSJ op-ed: Patients often pay full price for drugs that are sold to insurers at deep discounts.

Below, to show you why, I follow the dollar for an expensive, highly rebated brand-name drug used by a consumer with a high-deductible health plan. As you will see, the consumer pays more than twice the true discounted price of the drug. Meanwhile, the health plan pockets a large rebate.

That's the uncomfortable reality of the gross-to-net bubble that AHIP wants to hide. Insurers may not use rebates to lower the out-of-pocket costs for the patient whose prescription generated the rebate. And at the same time, AHIP indignantly blames "the prices drugmakers set." We all deserve better.

Tuesday, February 19, 2019

CBI’s 4th Edition Drug Pricing Transparency Congress

CBI’s 4th Edition Drug Pricing Transparency Congress
March 25-26, 2019 | Philadelphia, PA
www.cbinet.com/drugpricing

From implementation and changes made across the country in states like Oregon, California and Nevada to the release of the long-awaited HHS proposed rebate rule, complexities continue to arise for industry. According to HHS Secretary Alex Azar, this proposal “has the potential to be the most significant change in how Americans’ drugs are priced at the pharmacy counter, ever.”

With all that is going on with drug pricing within state and federal laws, uncertainty arises for stakeholders with responsibilities in commercialization, reimbursement, pricing and compliance practices. Is your organization prepared to act? And fast?

Join CBI’s 4th Edition Drug Pricing Transparency Congress to strategize and gain best practices regarding drug pricing transparency to overcome challenges and remain compliant.

Register by Friday, March 15 and save $300* off the standard rate with promo code DCB300.

Key Topics Addressed:
  • Pre-Conference Workshop (March 25): Medicare Drug Pricing and Reimbursement – Deep Dive into the Emerging International Pricing Model
  • Review drug pricing transparency legislation and litigation — Including a deep-dive, state-by-state analysis of laws in Oregon, California and Nevada
  • Explore how the future of drug pricing transparency regulation and the proposal to exclude rebates will impact commercialization, reimbursement and drug pricing models
  • Deliver comprehensive legal interpretations of drug pricing transparency and reporting laws currently on the books and the policy outlook for 2019
  • Benchmark overall state compliance practices related to drug pricing reporting
  • Discuss organizational shifts within legal and compliance departments to handle drug pricing obligations and reporting
Hear from Industry Experts, Including:
  • Debbie A. Walters-Francique, Vice President, Assistant General Counsel, Pfizer Inc.
  • John A. Murphy III, Deputy General Counsel, BIO
  • Amie Phillips Pablo, Associate Director, Compliance Government Reporting, Novo Nordisk
  • Brian A. Bohnenkamp, Partner, FDA & Life Sciences Practice, King & Spalding LLP
  • William Harris, Assistant General Counsel, US Market Access, Sanofi
  • Susan Hibbard, Senior Manager, Transparency and Disclosure, Ethics and Compliance, Boehringer Ingelheim
  • David Gibbons, Associate, Hyman, Phelps & McNamara, P.C.
  • Joanne Chan, Assistant General Counsel, PhRMA
  • Kendra Martello, Senior Director, Public Policy, Government Affairs and Public Policy, Mallinckrodt Pharmaceuticals
  • James Kim, Attorney, McDermott Will & Emery LLP
  • Sarah diFrancesca, Partner, Cooley LLP
  • Trevor L. Wear, Partner, Sidley Austin LLP
Don't miss this critical dialogue. Register by Friday, March 15 and save $300* off the standard rate with promo code DCB300.

*Offer expires 3/15/19; applies to standard rates only and may not be combined with other offers, category rates, and promotions or applied to an existing registration.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Friday, February 15, 2019

Pharmacy Fraud Within Pharmaceutical Co-Pay Programs: What You Need To Know

Today’s guest post comes from Tim Ogren, Senior Vice President, Products at TrialCard.

Tim discusses the rise in pharmacies making fraudulent claims and the costs of these claims. Learn more in Trialcard’s white paper: Detecting Pharmacy Fraud: Is Your Brand’s Co-Pay Program Protected?

TrialCard developed Spotlight®, a pharmacy fraud detection product for manufacturers. To learn more, contact Tim Ogren, TrialCard’s Senior Vice President of Products, at tim.ogren@trialcard.com.

Read on for Tim’s insights.

Thursday, February 14, 2019

Preorder Now: Our 2019 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

On March 5, 2019, Drug Channels Institute will release The 2019 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers.

This new tenth edition is the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing and distribution system.

The 2019 edition has been significantly expanded and restructured since last year’s edition. We have added new industry data sources, deepened our coverage of many topics, and added more trending information. There are also 2 new chapters and many new exhibits.


This year, we are providing you with the opportunity to preorder this thoroughly updated and revised 2019 edition at special discounted prices. This means that you can be among the first to access our new report. Those who preorder will receive a download link before March 5.

You can pay online with all major credit cards (Visa, MasterCard, American Express, and Discover) or via PayPal. Click here to email us if you would like to pay by corporate purchase order or check.

Special pricing discounts will be valid through March 22, 2019.

As always, thank you for your interest in our work. If you have any questions before purchasing a license to the report, please email me. Enjoy!

Tuesday, February 12, 2019

Express Scripts Confirms It (Again): Minimal Growth in Drug Spending and Prescription Costs

Last week, Express Scripts released its 2018 Drug Trend Report. (Free download.)

As you will see below, drug spending is not “skyrocketing” or “soaring.” All payer types experienced extremely low growth in pharmacy benefit spending. Average net (post-rebate) drug costs declined.

These data also shed light on specialty drug spending. Greater use of specialty medications—not cost increases—was the most significant driver of spending.

The latest Express Scripts data confirm the cost and spending slowdown that I have highlighted in previous Drug Channels articles. I’ll ask again: Can someone please alert the media and our elected officials?

Meanwhile, the report dodges crucial questions about the effect on patients. Overall drug spending is growing very slowly—but the sickest Americans are stuck paying ever-higher out-of-pocket costs for drugs with net prices that are flat or declining. That's worse than getting an empty box of chocolates for Valentine's Day.

Monday, February 11, 2019

Expanded Access Programs 2019

Expanded Access Programs 2019
March 27-28, 2019 | The Inn at Penn | Philadelphia, PA
www.cbinet.com/EAP

CBI’s Expanded Access Programs 2019 focuses on the design, development and practical implementation of early access programs. The summit convenes top industry stakeholders and regulators to examine current approaches in providing investigational, pre-launch or end-of-lifecycle drugs to patients for treatment purposes. A multi-stakeholder faculty will address key issues affecting EAPs and review the potential impact of the evolving legislative landscape.

Drug Channels readers will save $300 off of the standard registration rate
when they use code AGK946.* REGISTER TODAY!

Join Expert Thought Leaders Including:
  • Marcel van Kuijck, Vice President UltraPrograms, Global Medical Affairs, Ultragenyx Pharmaceutical Inc.
  • Tom Watson, Executive Vice President, Early Access Programs, Bionical
  • Naomi Lopez Bauman, Director of Healthcare Policy, Goldwater Institute
  • Sharon Ellison, DUHS IRB Chair; pharmacist, Duke University Hospital
  • Gretchen M. Randlett, Consultant – Clinical Trial Commercial Product Strategy and Process, Eli Lilly and Company
  • Alison Bateman-House, Ph.D., MPH, MA, Assistant Professor, Division of Medical Ethics, NYU Langone Health; Co-Director, NYU School of Medicine Working Group on Compassionate Use and Preapproval Access (CUPA)
  • Dawn Sullivan, Department Manager, Global Medical Affairs & UltraPrograms, EAPs/ISTs, Ultragenyx Pharmaceutical Inc.
  • Erika Segear, Ph.D., RAC, Associate Director of Regulatory Affairs, Duke University
Key Topics to Be Addressed:
  • Implement practical guidelines for responding to inquiries around Right to Try
  • Assess whether there is an opportunity to seek reimbursement through traditional payer channels
  • Navigate the development process of sibling Early Access Programs
  • Bring the patient voice into the development of Early Access Programs
  • Learn how global organizations are handling new legislation on patient privacy
  • Explore how crowd funding bridges Right to Try, stem cell and new frontiers
  • Discuss post-clinical trial access when a program does not meet endpoints
This multi-stakeholder event is focused on U.S. and global models for a variety of access management programs, including, but not limited to:
Expanded Access Programs, Early Access Programs, Compassionate Use Programs, Named Patient Programs and Managed Access Programs.

Visit www.cbinet.com/EAP for more information.

Drug Channels readers will save $300 off of the standard registration rate
when they use code AGK946.* REGISTER TODAY!

*Applies to standard rates only and may not be combined with other offers, category rates, promotions or applied to an existing registration. Offer not valid on workshop only or academic/non-profit registrations.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Tuesday, February 05, 2019

My Wall Street Journal Op-Ed: Don’t Blame Drug Prices on ‘Big Pharma’

Yesterday, The Wall Street Journal published my op-ed: Don’t Blame Drug Prices on ‘Big Pharma’. The article text is pasted below for those who don't subscribe.

I wrote this piece for a general business audience, though my arguments about rebates and patient out-of-pocket costs will be familiar to regular readers of Drug Channels. Alas, I had to omit such insider terms as gross-to-net bubble, direct and indirect remuneration, and SpongeBob SquarePants.

A personal note: I have been reading the WSJ daily since I was 18 years old. It’s a genuine thrill to see my byline on an op-ed in this newspaper. Another item off my bucket list!

Monday, February 04, 2019

Partnering with IDNs BioPharma Strategy Summit West

Partnering with IDNs BioPharma Strategy Summit West
March 20-21, 2019 | Scottsdale, AZ
www.cbinet.com/IDN

As part of an evolving healthcare environment, the life science industry is continually challenged to be effective in how it engages health system partners. It is critical that discussions evolve to meet the needs of today and also where healthcare is headed tomorrow.

To address the challenges and opportunities ahead, join a distinguished group of industry pioneers at CBI’s Partnering with IDNs BioPharma Strategy Summit West – an important event for learning how to best meet the needs of these evolving networks for better patient outcomes.


Drug Channels subscribers will save $400 off the standard registration rate
when they use promo code RMD779* by March 1, 2019.

Diverse Perspectives from Industry Pioneers:
  • Matthew Portch, Vice President, Managed Markets, Sunovion
  • Marla Weigert, Vice President, System Pharmacy Services, President, Dignity Specialty Pharmacy
  • JD Fischer, Sr. Health Policy Analyst, Policy Division, Washington State Healthcare Authority
  • John Robicsek, Assistant Vice President, Strategy, Business and Program Development, Pharmacy Administration, Atrium Health
  • Jacob Jolly, Program Director, Specialty Pharmacy, Vanderbilt University Medical Center
  • Melissa Leedock, Director Pharmacy Formulary and Commercial Operations, Pharmacy Services, Capital Blue Cross
  • Jay Weaver, PharmD, MPH, Divisional Vice President, Enterprise Pharmacy, Blue Cross and Blue Shield of Illinois, Montana, New Mexico, Oklahoma & Texas
  • John Musil, Founder and Chairman, Avella Specialty Pharmacy
  • Dawn Bina, Account Manager, BioPharm, Novo Nordisk Inc.
  • Lauren Vela, Senior Director, Member Value, Pacific Business Group on Health
Discuss Innovative Partnership Models, Compare Population Health Management Strategies and:
  • Explore employer trends in cost sharing, utilization management, pharmacy network strategy and more
  • Assess the best approach for working with providers on data collection and integrity
  • Discuss how to take pilot key learnings and craft a meaningful IDN value story
  • Consider engagement strategies for risk-based contracting with evolving IDNs
  • Examine the different approaches to IDN-SP integration and how manufacturers can utilize this information for strategic planning
  • Describe the benefits of collaboration across the industry to optimize and standardize outcomes reporting
  • Plus! Benefit from 12+ hours of networking with manufacturers, health systems, payers, specialty pharmacies
  • And More!

Visit www.cbinet.com/IDN for more information. Drug Channels subscribers will save $400 off the standard registration rate when they use promo code RMD779* by March 1, 2019.

*Offer expires 3/1/19, applies to standard rates only and may not be combined with other offers, category rates, promotions or applied to an existing registration. Offer not valid on workshop only or academic/non-profit registrations.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Friday, February 01, 2019

Shaping an Effective Data and Analytics Strategy for Your Oncology Therapy in 2019

Today’s guest post comes from Derek Rago, VP/GM of Data, Evidence & Insights at McKesson Life Sciences.

Derek discusses how biopharma companies can use real-world evidence to gain efficiencies and build effective strategies. He also outlines the key elements of an effective data and analytics strategy.

To learn more about McKesson’s data, evidence and insights solutions, visit McKesson.com/DataInsights.

Read on for Derek’s insights.

Thursday, January 31, 2019

Drug Channels News Roundup, January 2019: Part D Plan Profits, Hospitals vs. Drugs, and BS in Healthcare

L.A. vs. New England! Youth vs. experience! Kale vs. chowdah! Yes, it’s time for a weekend of blow-out commercials, occasionally interrupted by a football game.

Before you start training to gorge at your Super Bowl-party, tackle this month’s selection of notable news stories, intercepted for you from the Drug Channels gridiron.
  • Touchdown: The little-known ways that plans profit from Medicare Part D
  • Trick play: Hospital care vs. prescription drugs: My best tweet ever!
  • Offensive lines: A must-read guide to BS in healthcare
Plus, we here at Drug Channels have just released our 2019 media kit. Check it out and let us know how we can help you appear on the site.

P.S. Follow my curated links to cool stuff at @DrugChannels on Twitter.

Tuesday, January 29, 2019

Drug Prices Are NOT Skyrocketing—They’re Barely Growing at All

The IQVIA Institute for Human Data Science today released a new report that reveals important realities about U.S. drug pricing trends.

Too many politicians and journalists remain committed to the false narrative of “skyrocketing” and “soaring” drug prices.

By contrast, IQVIA data reveal that list prices for brand-name drugs grew by less than 6% in 2018. What’s more, net prices (after rebates and discounts) increased by only 1.5%. The 2018 figures mark the fourth consecutive year that net drug prices have grown by low-single-digit amounts.

I recognize that relying on “facts” and “data” has become unfashionable. But I simply don’t understand how we can build sound public policies based upon inaccurate perceptions. As the late senator Daniel Patrick Moynihan said: "Everyone is entitled to his own opinion, but not his own facts." I doubt this principle will guide today's congressional hearings.

Monday, January 28, 2019

sPCMA Business Forum

sPCMA Business Forum
March 11 & 12, 2019
Hilton Bonnet Creek | Orlando, FL

The sPCMA Business Forum brings together senior executives and decision makers from PBMs, health plans and their affiliate specialty pharmacies to collaborate with drug makers and their other important business partners. The event offers invaluable networking and education for individuals and companies involved in the specialty drug supply chain. Conference sessions will cover critical issues confronting the work of PBMs, insurers and drug makers.


Contact PCMA

Please contact Jenny Bradham (jbradham@pcmanet.org) with questions or to request further information.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.


Wednesday, January 23, 2019

New Part D Enrollment Data: CVS Extends Its Lead in 2019 Preferred Pharmacy Networks

The Centers for Medicare & Medicaid Services (CMS) has just released its first 2019 data on enrollment in Medicare Part D prescription drug plans (PDPs).

Our exclusive analysis of these numbers finds that for 2019, 88.4% of seniors are enrolled in PDPs with preferred pharmacy networks. That’s a drop from last year's figure of 99.9%.

Below, we use the new enrollment data to analyze the major pharmacy chains’ position within the 22 major Part D plans that have preferred networks. As you will see, in 2019 CVS again looks poised to capture market share from Walgreens and Walmart, both of which lost position in this year’s networks. Kroger remains a major player, while Rite Aid holds a distant fourth place behind its peers.

One more fun fact about 2019 enrollment: CVS Health’s SilverScript Allure, the first Part D plan with point-of-sale (POS) rebates for brand-name drugs, bombed. Was it a noble experiment or an unappealing option designed to enroll few seniors in a plan design that CVS opposes?

Tuesday, January 22, 2019

CBI’s 15th Annual Life Sciences Accounting & Reporting Congress

CBI’s 15th Annual Life Sciences Accounting & Reporting Congress
March 20-22, 2019 | Loews Philadelphia Hotel | Philadelphia, PA
www.cbinet.com/accounting

As product pricing and contracting within the channel continues to tangle in complexity, and the gross-to-net “bubble” swells in size, leaders in Finance and Accounting are often at the front lines, making decisions around strategy and reporting.

CBI’s 15th Annual Life Sciences Accounting & Reporting Congress, the world’s top event for finance, accounting and business leaders within life sciences, provides the in-depth CPE education and networking with nearly 600 professionals.

Visit www.cbinet.com/accounting for further details and to register. Drug Channels readers will save $400 off the standard rate when they use promo code SNQ255 and register prior to February 8th.*

Hot topics include: SEC reporting, R&D financing, product pricing and contracting, critical audit matters, GTN, robotic process automation, valuation, collaborations and licensing, capital creation and allocation, SOX compliance, M&A, corporate tax, new product commercialization, FP&A, cybersecurity and data privacy, carve-outs and divestitures, revenue recognition, forecasting and financial planning, leases, and third-party oversight. You’ll return to the office ready to advance your organization to stay ahead in 2019.

You can sign up to view the agenda here, and see a snapshot of what you can expect:
  • CEO Fireside ChatCandid Conversation on Key Business and Industry Topics
    Featuring Cathy Engelbert, CEO, Deloitte and Heather Bresch, CEO, Mylan
  • CFO Keynote PanelLeading in Finance and Navigating the Course of Change
    Led by Laura Robinette, US Pharmaceutical and Life Sciences Assurance Leader, PwC and Featuring Chief Financial Officers from Endo, Impax/Amneal and Insmed Incorporated
  • Women’s Leadership Summit - Stories on Career Development, Leadership and Mentorship
    Featuring PwC, Shire, Covance, Ipsen and Solid Biosciences
  • Wall Street and Investment PanelImpactful Deals Impacting the Life Science Marketplace
    Featuring Achillion Pharmaceuticals, Bain Capital, Bank of America Merrill Lynch and PwC
Additional sessions to be presented by Alnylam Pharmaceuticals, Adamas Pharmaceuticals, Johnson & Johnson, Allergan, BMS, Ironwood Pharmaceuticals, Pfizer, Boston Scientific, Medtronic, AMAG Pharmaceuticals, AnaptysBio, Spero Therapeutics, and many others.

Visit www.cbinet.com/accounting for further details and to register. Drug Channels readers will save $400 off the standard rate when they use code SNQ255 and register prior to February 8th.*
CBI will see you there!

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rate or non-profit rates. Other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Tuesday, January 15, 2019

Independent Pharmacy Economics Keep Deteriorating

Time for Drug Channels’annual look at independent pharmacy owners’ business economics, drawn from the recently released 2018 National Community Pharmacists Association (NCPA) Digest, Sponsored by Cardinal Health. Here's the press release: NCPA Releases 2017 Digest.

Below, I update our estimates on pharmacy economics and margins. Our analysis reveals that independent pharmacy owners have faced another year of deteriorating finances.

What's more, we estimate that in 2017, the average pharmacy owner’s salary fell to a level comparable to that of an employed pharmacist. Owning a pharmacy, with all of its hassles and additional obligations, now brings the same reward as being an employee. I wonder how many owners will conclude that it’s barely worth the risk and effort.

Read on for our look at pharmacy profits and some comments on the industry’s competitive dynamics, including the financial impact of direct and indirect remuneration (DIR) fees.

The pharmacy consolidation endgame is getting closer. The next time you see a pharmacy owner, offer your condolences.

Monday, January 14, 2019

CBI’s 6th Annual e-Rx and EHR

CBI’s 6th Annual e-Rx and EHR
March 12-13, 2019 | The Inn at Penn | Philadelphia, PA
www.cbinet.com/erx

CBI’s 6th Annual e-Rx and EHR conference, taking place March 12-13 in Philadelphia, provides tangible takeaways and tailored sessions to help you understand how to maximize e-prescribing and EHR technology engagement. Don’t miss the major key insights from industry thought-leaders as they discuss the challenges with streamlining HCP workflow, refined strategies for educating patients and best practices in coordinating channel integration with EHR platforms.

Download the agenda for complete details and register by Friday, February 8, 2019 and receive $300* off the standard rate with promo code DCX300.

Featured Discussion Topics:
  • Discuss the e-prescribing provisions within the SUPPORT for Patients and Communities Act of 2018
  • Examine current initiatives within Apple, Amazon and the City of Philadelphia and how they are becoming three key players in the EHR space
  • Evaluate early clinical factors and treatment of patients to a specific therapeutic area for quality care
  • Hear innovative insights into the efforts of Geisinger and Merck with MedTrue™
  • Review what providers are looking for and assess the gaps in using EHRs
  • Discuss current patient support tools and resources that truly drive physician and patient engagement in population health management
  • Learn to deliver patient-specific drug benefit and cost-information within the e-prescribing workflow at the point of care
  • Understand the value of data analytics in regards to prescribing patterns
Expert Multi-Stakeholder Speaking Faculty:

PHYSICIAN PERSPECTIVE:
  • David Kaelber, M.D., Chief Medical Informatics Officer, The MetroHealth System
PAYER PERSPECTIVE:
  • Kimberly Hansen, Director, Network Operations, UnitedHealthcare
HEALTH SYSTEM PERSPECTIVE:
  • Julie K. Rockey, MBA, RHIA, Strategic Program Director, Geisinger Health System
MANUFACTURER PERSPECTIVES:
  • Eric Wente, Regional Account Executive, Market Access US, Bayer Healthcare Pharmaceuticals, Inc.
  • Patricia Cunningham, MSHI, RHIA, CHPS, Associate Director, Health IT, Boehringer Ingelheim
  • Mark Monticelli, Associate Director, Health Systems Marketing, Astellas
  • Vanessa Menton, Director, Oncology Marketing, Astellas
Don't be left out of the conversation. Download the agenda for complete details and register by Friday, February 8, 2019 and receive $300* off the standard rate with promo code DCX300.

*Offer expires Friday, February 8, 2019; applies to standard rates only and may not be combined with other offers, category rates, and promotions or applied to an existing registration.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Tuesday, January 08, 2019

The Big Three Generic Drug Mega-Buyers Drove Double-Digit Deflation in 2018. Stability ahead?

Oral generic drugs keep getting cheaper. The Food & Drug Administration (FDA) has intensified the generic industry’s competitive pressures with record drug approvals. The FDA’s actions, combined with the negotiating leverage of the large generic purchasing organizations, led to 2018’s persistent double-digit deflation in manufacturers’ selling prices for oral generic drugs.

Below, we update our analysis of these generic drug mega-buyers.

We estimate that for 2018, the three largest buyers  accounted for more than 90% of total U.S. generic drug purchases from manufacturers. In 2019, acquisitions and contract switches will shift market share among these groups, but not diminish their impact. It's no surprise that manufacturers lose their minds when seeing these monster firms.

There are now fewer therapeutic areas with excess inflation, so future price reductions will be smaller. What’s more, some generic manufacturers have signaled their intention to exit highly competitive generic drug categories in which prices have dropped. Look for oral generic prices to stabilize—and possibly rise—over the next 12 to 18 months. Perhaps the blindfolds will come off?

P.S. Portions of this post have been adapted from our forthcoming 2019 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. We'll be taking this updated and expanded edition out of our bird box on March 5!

Monday, January 07, 2019

CBI’s 20th Annual Patient Assistance & Access Programs – PAP 2019

CBI’s 20th Annual Patient Assistance & Access Programs – PAP 2019
March 4-6, 2019 | Baltimore, MD
www.cbinet.com/pap

During a time when copay programs and patient support are under intense scrutiny and underinsurance continues to plague many patients, PAP 2019 convenes over 450 leaders from the patient assistance and product access field (manufacturers, copay foundations, non-profits, free clinics, advocacy organization, hospitals) to prepare you for what’s ahead. Join over 50 distinguished speakers who are prepared to address the legal environment, industry best practices and policy watch-outs related to prescription access and financial assistance.

Drug Channels readers save $400 off the standard rate when they
use discount code REK226 and register prior to January 25th.*

You can download the agenda here and see in-depth coverage on critical issues, such as:
  • The Impact of Copay Accumulators on Access and Adherence
  • Legal Underpinnings of Patient Assistance and Gain Insight on OIG Oversight
  • Technology and Automation Tools that are Improving the Patient Journey and Outcomes
  • Advancements in Electronic Benefit Verification
  • Strategies for Effectively Managing Patient Data
  • Patient-Centric Support Programs to Remove Barriers and Support Adherence
    Navigating Changes and Ensuring Coverage for Medicare Patients
  • Trends and Approaches in Nursing Support Programs
Visit www.cbinet.com/pap for further details and to register. Drug Channels readers will save $400 off the standard rate they use discount code REK226 and register prior to January 25th.*

CBI will see you there!

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates, clinic/hospital rates, non-profit rates other offers. Other restrictions may apply</>.



The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Thursday, January 03, 2019

Specialty Pharmacy M&A: Our Look at 2018’s Deals

Let’s kick off 2019 with a quick review of last year’s specialty pharmacy mergers and acquisitions (M&A). Our list (below) includes only deals that were publicly announced in 2018.

Pharmacy benefit managers (PBMs) were especially busy. CVS Health bought five specialty pharmacies. UnitedHealth’s OptumRx bought Avella Specialty Pharmacy, the largest independent specialty pharmacy.

Diplomat Pharmacy was uncharacteristically quiet during 2018, though it had been one of the most active acquirers in previous years.

The specialty pharmacy industry is rapidly maturing, so I expect many more exits in the coming years. Looking to pick up a fast-growing specialty pharmacy? Click here for your post-holiday shopping list.